Search research articles
Contact Us
Filters
Showing results (101-110 of 271) with videos related to
Page
of 28
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
April 1, 2014
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma
Naamit K Gerber, Yoshiya Yamada, Andreas Rimner, et al.
Nature Medicine
|
November 9, 2019
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
Diego Chowell, Chirag Krishna, Federica Pierini, et al.
Signal Transduction and Targeted Therapy
|
July 31, 2021
Multimodal single-cell omics analysis identifies epithelium-immune cell interactions and immune vulnerability associated with sex differences in COVID-19
Yuan Hou, Yadi Zhou, Michaela U Gack, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 10, 2017
Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5×6Gy) conformal radiotherapy
Natalie A Lockney, Diana G Wang, Philip H Gutin, et al.
JAMA Network Open
|
March 20, 2025
Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal Cancer
Shahla Bari, Marco Matejcic, Richard D Kim, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 2, 2013
Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy
Ian Ganly, Julio Ricarte Filho, Stephanie Eng, et al.
Nature Communications
|
February 28, 2019
G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma
Yuxiang Wang, Jie Yang, Aaron T Wild, et al.
The Lancet. Oncology
|
November 13, 2018
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study
Martin H Voss, Albert Reising, Yuan Cheng, et al.
Science Advances
|
June 5, 2020
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
Yuxiang Wang, Aaron T Wild, Sevin Turcan, et al.
BMC Cancer
|
March 1, 2018
Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
Kim A Brogden, Deepak Parashar, Andrea R Hallier, et al.
Page
of 28
Search research articles
Search
Showing results (101-110 of 271) with videos related to
Sort By:
Page
of 28
International Journal of Radiation Oncology, Biology, Physics
|
April 1, 2014
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma
Naamit K Gerber, Yoshiya Yamada, Andreas Rimner, et al.
Nature Medicine
|
November 9, 2019
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
Diego Chowell, Chirag Krishna, Federica Pierini, et al.
Signal Transduction and Targeted Therapy
|
July 31, 2021
Multimodal single-cell omics analysis identifies epithelium-immune cell interactions and immune vulnerability associated with sex differences in COVID-19
Yuan Hou, Yadi Zhou, Michaela U Gack, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 10, 2017
Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5×6Gy) conformal radiotherapy
Natalie A Lockney, Diana G Wang, Philip H Gutin, et al.
JAMA Network Open
|
March 20, 2025
Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal Cancer
Shahla Bari, Marco Matejcic, Richard D Kim, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 2, 2013
Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy
Ian Ganly, Julio Ricarte Filho, Stephanie Eng, et al.
Nature Communications
|
February 28, 2019
G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma
Yuxiang Wang, Jie Yang, Aaron T Wild, et al.
The Lancet. Oncology
|
November 13, 2018
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study
Martin H Voss, Albert Reising, Yuan Cheng, et al.
Science Advances
|
June 5, 2020
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
Yuxiang Wang, Aaron T Wild, Sevin Turcan, et al.
BMC Cancer
|
March 1, 2018
Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
Kim A Brogden, Deepak Parashar, Andrea R Hallier, et al.
Page
of 28